title: Management of bleeding GI tumors.
authors.affiliation: Department of Medicine, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA.
authors.forename: Stephen J
authors.initials: SJ
authors.lastname: Heller
authors.forename: Jeffrey L
authors.initials: JL
authors.lastname: Tokar
authors.forename: Minhhuyen T
authors.initials: MT
authors.lastname: Nguyen
authors.forename: Oleh
authors.initials: O
authors.lastname: Haluszka
authors.forename: David S
authors.initials: DS
authors.lastname: Weinberg
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D015179:Colorectal Neoplasms / Q000150:complications; D015897:Comorbidity; D004564:Electrocoagulation / Q000379:methods; D006471:Gastrointestinal Hemorrhage / Q000453:epidemiology / Q000209:etiology* / Q000628:therapy*; D005770:Gastrointestinal Neoplasms / Q000150:complications* / Q000453:epidemiology; D016558:Hemostasis, Endoscopic; D006801:Humans; D008028:Light Coagulation; D009503:Neutropenia / Q000453:epidemiology; D012004:Rectal Neoplasms / Q000150:complications; D013274:Stomach Neoplasms / Q000150:complications; D013921:Thrombocytopenia / Q000150:complications
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab